Goldman Sachs’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Goldman Sachs’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,112	Closed	-$182K	–	6001
2023 Q4	$182K	Buy	18,112 +2,132	+13%	+$9.68K	﹤0.01%	5180
2023 Q3	$46K	Sell	15,980 -1,274	-7%	-$4.66K	﹤0.01%	5285
2023 Q2	$65.7K	Sell	17,254 -215	-1%	-$602	﹤0.01%	5426
2023 Q1	$32.5K	Sell	17,469 -2,992	-15%	-$6.25K	﹤0.01%	5613
2022 Q4	$47.1K	Sell	20,461 -2,858	-12%	-$8.75K	﹤0.01%	5604
2022 Q3	$75K	Sell	23,319 -959	-4%	-$3.12K	﹤0.01%	5745
2022 Q2	$134K	Sell	24,278 -80,141	-77%	-$249K	﹤0.01%	5770
2022 Q1	$243K	Buy	104,419 +86,500	+483%	+$295K	﹤0.01%	5775
2021 Q4	$108K	Buy	+17,919	New	+$172K	﹤0.01%	6110

Goldman Sachs's GRCL Position: Q1 2024 in Review

Goldman Sachs sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 18,112 shares — an estimated $182K sold.

Goldman Sachs first reported a position in GRCL in Q4 2021 and held it in 9 quarters. The position peaked at $243K in Q1 2022. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Goldman Sachs reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Goldman Sachs sold 18,112 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $182K.
Goldman Sachs first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2021 and held it in 9 quarters.
Goldman Sachs's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $243K in Q1 2022.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.